About sacituzuma b govitecan
Trop-2-directed antibody-drug conjugate
Used for
- Treats certain advanced or metastatic triple-negative breast cancers.
- Treats certain advanced or metastatic hormone receptor-positive, HER2-negative breast cancers.
Usual adult dose
10 mg/kg intravenously on days 1 and 8 of each 21-day cycle; continue until progression or unacceptable toxicity.
Common side effects
- Diarrhea, nausea, vomiting, constipation, and reduced appetite.
- Low white blood cell counts, anemia, and infections.
- Hair loss, fatigue, and abdominal pain.
Important warnings
- Can cause severe diarrhea; prompt treatment may be needed.
- Can cause serious low white blood cell counts and infections.
- May cause severe allergic or infusion reactions.
- Can harm an unborn baby; pregnancy testing and effective contraception are recommended.
Pregnancy
May cause fetal harm. Avoid during treatment and for 6 months after the last dose.
Breastfeeding
Do not breastfeed during treatment or for 1 month after the last dose.
Interactions
- UGT1A1 inhibitors may increase exposure and toxicity.
- UGT1A1 inducers may reduce exposure and effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.